GlassScriptPhysician profile
Bernard Schayes
NPI 1013986777
$10,290.70
in general payments reported to CMS, 2019-2025
36 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,422 · 2020: $682 · 2021: $826 · 2022: $1,974 · 2023: $2,125 · 2024: $1,598 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,301 · Education: $85.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,301.18 |
| Education | $85.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,205.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,276.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $992.24 | 2019-2025 | Jardiance |
| Bausch Health US, LLC | $655.51 | 2021-2025 | Aplenzin, Wellbutrin |
| Abbvie INC. | $565.08 | 2021-2025 | Ubrelvy, Viberzi, Linzess |
| Pfizer INC. | $504.45 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $487.67 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $440.14 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $312.47 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $293.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $268.41 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.06 | 2019-2025 | Trintellix |
| Esperion Therapeutics, INC. | $223.17 | 2022-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $212.87 | 2020-2025 | |
| Antares Pharma, INC. | $206.53 | 2019-2024 | Xyosted |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Schayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.